Translational Development Acquisition Corp. Ordinary Shares (TDAC) Stock Analysis

Sector: FINANCIAL SERVICES - SHELL COMPANIES

Exchange: NASDAQ

Key Metrics

• Price: $10.53
• Market Cap: $230.69M
• P/E Ratio: 47.86
• EPS: $0.22
• 52-Week High: $10.56
• 52-Week Low: $10.02

About Translational Development Acquisition Corp. Ordinary Shares

Translational Development Acquisition Corp. (TDAC) is a special purpose acquisition company (SPAC) based in New York, focused on identifying and partnering with innovative companies in the life sciences sector. The firm aims to leverage its team’s expertise to accelerate growth and deliver transformative healthcare solutions by facilitating mergers and acquisitions. With a strategic vision to capitalize on emerging markets within biotechnology and pharmaceuticals, TDAC is well-positioned to c...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Translational Development Acquisition Corp. Ordinary Shares and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does TDAC pay dividends?

Translational Development Acquisition Corp. Ordinary Shares (TDAC) does not currently pay a regular dividend.

What is TDAC's P/E ratio?

Translational Development Acquisition Corp. Ordinary Shares has a price-to-earnings (P/E) ratio of 47.86.

What is TDAC's market cap?

Translational Development Acquisition Corp. Ordinary Shares (TDAC) has a market capitalization of $230.69M with a current stock price of $10.53.